Vidac Pharma in the Media
Analyst coverage, investor reports, and media features
Vidac Pharma – A new approach is gaining momentum
There has long been a paradigm in oncology: the search for specific target molecules on tumor cells in order to eliminate them in a targeted manner. The biotech company Vidac Pharma is now pursuing a radically different path. Instead of flipping a single switch, the technology aims to reprogram the entire derailed metabolism of a cancer cell. The idea is to get the cell to behave normally again and ultimately initiate programmed cell death. This systemic approach could be a game changer, as it addresses a fundamental characteristic of almost all tumors. Read More
Read full articleImportant piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.
The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this? Read More
Read full articleImportant piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.
The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this? Read More
Read full articleVidac Pharma is betting everything on the Warburg effect – Promising approaches
Current research approaches to the Warburg effect focus on depriving cancer cells of nutrients on the one hand and oxidative stress on the other, which makes other therapies more effective. The biotech company Vidac Pharma is fully committed to reversing the Warburg effect and focuses primarily on active ingredients for skin and liver cancer. In particular, VDA-1275 , a drug candidate for solid tumors , has recently caused a stir: Preclinical studies have shown that VDA-1275 can increase the efficacy of chemotherapeutic agents against liver cancer by a factor of 1000. Read More
Read full articleVidac Pharma is betting everything on the Warburg effect – Promising approaches
Current research approaches to the Warburg effect focus on depriving cancer cells of nutrients on the one hand and oxidative stress on the other, which makes other therapies more effective. The biotech company Vidac Pharma is fully committed to reversing the Warburg effect and focuses primarily on active ingredients for skin and liver cancer. In particular, VDA-1275 , a drug candidate for solid tumors , has recently caused a stir: Preclinical studies have shown that VDA-1275 can increase the efficacy of chemotherapeutic agents against liver cancer by a factor of 1000. Read More
Read full articleVidac Pharma cuts off cancer cells' power supply – Top results with skin cancer cream
One company that could grow particularly dynamically due to its unique position is Vidac Pharma. Vidac's business model is based on a unique approach: reversing the Warburg effect. Cancer cells prefer to use glucose fermentation (Warburg effect) for energy, which leads to high glucose consumption and tumor growth. Vidac develops innovative active ingredients that detach the enzyme hexokinase-2 (HK2) from mitochondrial channels in order to normalize the degenerate metabolism of cancer cells. This blockade is intended to stop cell division and enable cell death to occur again. Vidac Pharma currently has two promising candidates – an ointment for skin cancer, which is in Phase 2 of clinical trials, and an active ingredient for solid tumors. The ointment for skin cancer in particular has shown impressive initial results: in an open-label study with patients with cutaneous T-cell lymphoma (CTCL stage I), the objective response rate was 56%. Complete remission was achieved in 22% of the subjects within eight weeks, and partial remission was observed in 34% of the study participants after eight to twelve weeks. All participants in the study remained progression-free for over four months, meaning that the cancer did not continue to grow. Read More
Read full articleVidac Pharma cuts off cancer cells' power supply – Top results with skin cancer cream
One company that could grow particularly dynamically due to its unique position is Vidac Pharma. Vidac's business model is based on a unique approach: reversing the Warburg effect. Cancer cells prefer to use glucose fermentation (Warburg effect) for energy, which leads to high glucose consumption and tumor growth. Vidac develops innovative active ingredients that detach the enzyme hexokinase-2 (HK2) from mitochondrial channels in order to normalize the degenerate metabolism of cancer cells. This blockade is intended to stop cell division and enable cell death to occur again. Vidac Pharma currently has two promising candidates – an ointment for skin cancer, which is in Phase 2 of clinical trials, and an active ingredient for solid tumors. The ointment for skin cancer in particular has shown impressive initial results: in an open-label study with patients with cutaneous T-cell lymphoma (CTCL stage I), the objective response rate was 56%. Complete remission was achieved in 22% of the subjects within eight weeks, and partial remission was observed in 34% of the study participants after eight to twelve weeks. All participants in the study remained progression-free for over four months, meaning that the cancer did not continue to grow. Read More
Read full articleVidac Pharma – Innovative pioneer in oncology
Vidac Pharma is positioning itself as a pioneer in cancer research with two promising drug candidates, VDA-1275 and VDA-1102. Both aim to reverse the disturbed metabolism of tumor cells. This approach represents an entirely new treatment method. While VDA-1275 has shown synergies with established chemotherapies in preclinical studies, the topical ointment VDA-1102 targets skin cancers such as cutaneous T-cell lymphoma. The portfolio is complemented by ALMAVID, a tumor microenvironment modifier that is now the focus of an international research consortium. Read More
Read full articleVidac Pharma: Strong news flow - Will the stock turn around?
Vidac Pharma's stock currently offers very exciting catch-up potential. The share price development is clearly lagging behind the positive news flow. Analysts even believe that the share price could multiply. The key price drivers are the two oncological and onco-dermatological drug candidates, VDA-1275 and VDA-1102. They are based on Vidac's patented approach of reversing the malignant metabolism of cancer cells and restoring normal cell function. This would represent a new class in cancer treatment. Read More
Read full articleVidac Pharma: Strong news flow - Will the stock turn around?
Vidac Pharma's stock currently offers very exciting catch-up potential. The share price development is clearly lagging behind the positive news flow. Analysts even believe that the share price could multiply. The key price drivers are the two oncological and onco-dermatological drug candidates, VDA-1275 and VDA-1102. They are based on Vidac's patented approach of reversing the malignant metabolism of cancer cells and restoring normal cell function. This would represent a new class in cancer treatment. Read More
Read full articleVidac Pharma scores with promising candidates and Prof. Herzberg
The two most important products are an ointment (VDA-1102) for an early form of skin cancer and cutaneous T-cell lymphoma, and the active ingredient VDA-1275, which targets solid tumors and has shown strong synergistic effects with chemotherapeutic agents already on the market in preclinical studies. The Company's CEO is Prof. Max Herzberg, who is considered one of the founding fathers of the Israeli biotech industry. His charisma could help convince researchers from the US to join Vidac Pharma. Even Israel and the UK could attract bright minds. Both countries score highly with low regulation for researchers. BioNTech, for example, is deliberately pushing ahead with a cancer research program in the UK. Read More
Read full articleVidac Pharma scores with promising candidates and Prof. Herzberg
The two most important products are an ointment (VDA-1102) for an early form of skin cancer and cutaneous T-cell lymphoma, and the active ingredient VDA-1275, which targets solid tumors and has shown strong synergistic effects with chemotherapeutic agents already on the market in preclinical studies. The Company's CEO is Prof. Max Herzberg, who is considered one of the founding fathers of the Israeli biotech industry. His charisma could help convince researchers from the US to join Vidac Pharma. Even Israel and the UK could attract bright minds. Both countries score highly with low regulation for researchers. BioNTech, for example, is deliberately pushing ahead with a cancer research program in the UK. Read More
Read full articleVidac Pharma: On the path to multiplication
At Vidac Pharma, positive news flow and share price performance remain disconnected. While the stock is now trading at just EUR 0.53 after starting the year at EUR 0.81, the Company is consistently working on a new class of cancer treatments. This presents an interesting buying opportunity. Incidentally, analysts at the German company Sphene Capital believe that the Vidac share price could multiply. Their target price is EUR 4.90. Read More
Read full articleVidac Pharma – A milestone for breakthrough therapies
In contrast to the Bayer Group, the biopharmaceutical company, led by Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is doing extremely well. The Company's approach is revolutionary. Vidac Pharma is developing anti-cancer drugs by altering the tumor's hyperglycolytic microenvironment and targeting the overexpression and mis-anchoring of the metabolic checkpoint hexokinase 2 in cancer cells to alter the tumor's microenvironment and selectively induce its programmed death without affecting the surrounding normal tissues. Read More
Read full articleVidac Pharma - New hope in cancer research
Vidac Pharma has attracted attention at the First Pediatric Brain Tumor Research Meeting in Jerusalem. Dr. Max Herzberg, CEO of the Company, presented data on the drug candidate VDA-1102, which successfully penetrated the blood-brain barrier in a 5-year-old patient as part of a special program. "_This is a significant milestone that opens up new possibilities for breakthrough therapies in brain diseases_ ," emphasized Herzberg. The ability to achieve therapeutic concentrations in the tumor could revolutionize the treatment of aggressive brain diseases, not only in children. Read More
Read full articleVidac Pharma is revolutionizing cancer therapy with the Warburg effect
The biopharmaceutical company Vidac Pharma is inspiring new confidence among investors and millions of patients undergoing oncology treatment. As a clinical-stage company, it is developing therapies that target cancer cells by reversing their aberrant metabolism – a trick that tumors use to survive. The compounds in Vidac's pipeline, such as VDA-1102 and VDA-1275, attack cancer cells where they differ from healthy cells: they use excessive sugar for energy – a phenomenon discovered by Nobel Prize winner Otto Warburg (Warburg effect). These approaches from Vidac Pharma boost the immune response and could enhance the effect of other therapies when used in combination. Read More
Read full articleVidac Pharma is revolutionizing cancer therapy with the Warburg effect
The biopharmaceutical company Vidac Pharma is inspiring new confidence among investors and millions of patients undergoing oncology treatment. As a clinical-stage company, it is developing therapies that target cancer cells by reversing their aberrant metabolism – a trick that tumors use to survive. The compounds in Vidac's pipeline, such as VDA-1102 and VDA-1275, attack cancer cells where they differ from healthy cells: they use excessive sugar for energy – a phenomenon discovered by Nobel Prize winner Otto Warburg (Warburg effect). These approaches from Vidac Pharma boost the immune response and could enhance the effect of other therapies when used in combination. Read More
Read full articleVidac Pharma – Groundbreaking progress
Vidac Pharma is one of the biotech shooting stars on the German stock market, with a share price increase of over 120% in the last 6 months. The Israeli company has a long history and is a pioneer in biopharmaceutical research. At the center of its oncology research is the Warburg effect, a phenomenon in which cancer cells metabolize glucose in large quantities. Vidac has developed a method that aims to inhibit hyperglycolysis and restore apoptosis in malignant cells. This targeted intervention could not only reduce the side effects of conventional chemotherapy but also make the tumor microenvironment adaptable to immune responses, increasing the effectiveness of other therapies. Read More
Read full articleVidac Pharma - On the way to next-gen cancer therapy
Vidac Pharma is positioning itself as an innovator with two highly interesting projects: The systemic agent VDA-1275 shows synergistic effects with chemotherapies in preclinical studies. In colorectal cancer models, the combination with Cisplatin reduced tumor size by around 39%. This could lead to reduced chemotherapy dosages and fewer side effects. At the same time, VDA-1102 stands out: Originally developed as an ointment for skin cancer, the newly formulated subcutaneous variant crosses the blood-brain barrier, leading to initial successes in pediatric brain tumors. The aim is to exploit the Warburg effect, a metabolic mechanism that could enable new cancer therapies. Read More
Read full articleVidac Pharma: On the path to multiplication
Will Vidac Pharma continue its rally soon? There is a good chance that the biotech highflyer of the second half of 2024 has ended its consolidation. The Company aims to revolutionize cancer treatment and has attracted much attention within the biotech industry and the capital market with convincing research results. The success story is expected to continue in the current year. It is quite possible that a takeover could take place in 2025, as the takeover merry-go-round in the oncology sector has been turning fast since last year. Read More
Read full articleVidac Pharma: New drug combination reduces cancer tumor size by 38.9% in preclinical study
Cancer ranks as the second leading cause of death in Germany, accounting for 22% of all deaths. According to Destatis, people between the ages of 40 and 74 are particularly affected by the insidious disease, with more men than women impacted (54% to 46%). Cardiovascular diseases are the most common cause of death. These alarming figures illustrate the ongoing need for innovative therapeutic approaches and sustainable research. Read More
Read full articleVidac Pharma: New drug combination reduces cancer tumor size by 38.9% in preclinical study
Cancer ranks as the second leading cause of death in Germany, accounting for 22% of all deaths. According to Destatis, people between the ages of 40 and 74 are particularly affected by the insidious disease, with more men than women impacted (54% to 46%). Cardiovascular diseases are the most common cause of death. These alarming figures illustrate the ongoing need for innovative therapeutic approaches and sustainable research. Read More
Read full articleBest of BioTech 2025 - BioNTech, Bayer, Pfizer, BioNxt, Defence Therapeutics, Evotec and Vidac Pharma
Biotechnological research in 2025 will be characterised by several key trends, technologies and social challenges. By utilising knowledge and money, mankind hopes to make progress in medicine, agriculture, the environment and industry. Whether it is cancer research, the development of new vaccines or the fight against diseases such as Alzheimer's, Parkinson's or multiple sclerosis. Science is making progress and must also cope with a difficult financing environment due to rising interest rates. Western industrialised countries are facing many challenges: Demographic changes, migration, epidemics and a multitude of geopolitical conflicts. For medicine and society, innovation remains a costly affair in many respects. But the sector is being kissed awake and investors are looking for investment opportunities that promise medium-term success. We make a selection of stocks that we want to highlight this year with a positive risk/reward profile. Read Full Article
Best of BioTech 2025 - BioNTech, Bayer, Pfizer, BioNxt, Defence Therapeutics, Evotec and Vidac Pharma
Biotechnological research in 2025 will be characterised by several key trends, technologies and social challenges. By utilising knowledge and money, mankind hopes to make progress in medicine, agriculture, the environment and industry. Whether it is cancer research, the development of new vaccines or the fight against diseases such as Alzheimer's, Parkinson's or multiple sclerosis. Science is making progress and must also cope with a difficult financing environment due to rising interest rates. Western industrialised countries are facing many challenges: Demographic changes, migration, epidemics and a multitude of geopolitical conflicts. For medicine and society, innovation remains a costly affair in many respects. But the sector is being kissed awake and investors are looking for investment opportunities that promise medium-term success. We make a selection of stocks that we want to highlight this year with a positive risk/reward profile. Read Full Article
Evotec, Vidac Pharma, BioNTech – Profiting from the fight against cancer
The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a genuine blockbuster. In 2023, around USD 223 billion was spent on cancer drugs worldwide. We are looking at three companies striving to cure cancer and claim their share of this lucrative market. Read More
Read full articleEvotec, Vidac Pharma, BioNTech – Profiting from the fight against cancer
The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a genuine blockbuster. In 2023, around USD 223 billion was spent on cancer drugs worldwide. We are looking at three companies striving to cure cancer and claim their share of this lucrative market. Read More
Read full articleVidac Pharma – Further milestones
Since the end of May of the past stock market year 2024, shares of the biopharmaceutical oncology company have risen by approximately 275% to EUR 0.74. According to the analyst firm Sphene Capital, the price target, which was already set around six months ago, is EUR 4.90, offering a further price potential of 562%. Read More
Read full articleVidac Pharma – Now entering Phase 2 and 3 with vigour
One of the top performers in the last 6 months was the biotech small-cap Vidac Pharma, with a price increase of over 150%. Founded in 2012, the Company is led by Prof Max Herzberg, one of the founding fathers of the Israeli life sciences industry. Vidac Pharma is developing drugs that will help cancer patients by reversing the abnormal metabolism of cancer cells, thus stopping the proliferation of these cells. Despite its modest size, the Company is already in the clinical development phase. Read More
Read full articleVidac Pharma: Innovative cancer therapy attracts early-stage investors
Morbid obesity can lead to an increase in 13 different types of cancer. According to the WHO's International Agency for Research on Cancer, these include pancreatic cancer, thyroid cancer and breast cancer (after menopause). However, the therapies for treating different types of cancer differ fundamentally. While surgical removal of the thyroid gland is usually the main treatment for thyroid cancer, lymphoma, for example, is treated mainly with chemotherapy and radiotherapy, affecting the patient's entire body. Read More
Read full articleVidac Pharma: Innovative cancer therapy attracts early-stage investors
Morbid obesity can lead to an increase in 13 different types of cancer. According to the WHO's International Agency for Research on Cancer, these include pancreatic cancer, thyroid cancer and breast cancer (after menopause). However, the therapies for treating different types of cancer differ fundamentally. While surgical removal of the thyroid gland is usually the main treatment for thyroid cancer, lymphoma, for example, is treated mainly with chemotherapy and radiotherapy, affecting the patient's entire body. Read More
Read full articleBiotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer
There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector. Read More
Read full articleBiotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer
There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector. Read More
Read full articleVidac Pharma - Progress in the fight against cancer
Vidac Pharma celebrated a significant milestone on September 19: The US Patent and Trademark Office (USPTO) has granted the biopharmaceutical company a broad patent that protects the unique mechanisms of its cancer therapies. This protection includes, in particular, the active ingredients VDA-1102 and VDA-1275, which specifically reverse the metabolic mechanism of cancer cells – known as the Warburg effect. Vidac Pharma is the only company in the world pursuing this approach. The goal is to normalize cell functionality, stop tumor growth and reactivate the immune system. With this exclusive position in the US market, the patent success paves the way for the further expansion of the product pipeline and strengthens the market position of the innovative company. Read More
Read full articleSphene Capital’s Top Analyst Confirms: Vidac Pharma Leading the Way in Revolutionary Cancer Treatment
An impressive report done by top analyst Herr Peter Thilo Hasler for Sphene Capital GmbH on Vidac Pharma shows what we already knew: our company is in the right direction and indeed the "buy" recommendation of this highly professional Analyst is a great compliment and confirmation that our focus is on the right path. Vidac Pharma is the only company we know of developing anti-cancer drugs by reversing the Warburg effect.
Read full articleSphene Capital’s Top Analyst Confirms: Vidac Pharma Leading the Way in Revolutionary Cancer Treatment
An impressive report done by top analyst Herr Peter Thilo Hasler for Sphene Capital GmbH on Vidac Pharma shows what we already knew: our company is in the right direction and indeed the "buy" recommendation of this highly professional Analyst is a great compliment and confirmation that our focus is on the right path. Vidac Pharma is the only company we know of developing anti-cancer drugs by reversing the Warburg effect.
Read full articleVidac Pharma – Capital injection boosts momentum
Vidac Pharma is one of the biotech shooting stars on the German stock market, with its share price having risen by over 230% in the last six months. The Company is now receiving a reinvestment of EUR 600,000 from shareholders to advance the clinical trials of its cancer drug candidates. Vidac will use the funds to conduct a series of clinical trials, including a second Phase 2b clinical trial of VDA-1102 in advanced actinic keratosis (AK), an early form of skin cancer that can develop into cutaneous squamous cell carcinoma (CSCC). Vidac is initiating the regulatory preparations for this study and has also signed a contract with the research dock CRO. Prof. Dr. Thomas Dirschka, one of the world's leading experts on AK and head of the leading dermatological research institute, CentroDerm GmbH, will be the principal investigator. Read More
Read full articleVidac Pharma: Breakthrough in cancer therapy with novel treatment approach
The British biotech company Vidac Pharma (ISIN GB00BM9XQ619) has reached an important milestone in the development of innovative cancer therapies. The US Patent Office has granted the Company a groundbreaking patent for a completely new therapeutic approach: the treatment aims to normalize the metabolism of cancer cells – an approach that experts refer to as "Warburg effect reversal". Read More
Read full articleVidac Pharma: Breakthrough in cancer therapy with novel treatment approach
The British biotech company Vidac Pharma (ISIN GB00BM9XQ619) has reached an important milestone in the development of innovative cancer therapies. The US Patent Office has granted the Company a groundbreaking patent for a completely new therapeutic approach: the treatment aims to normalize the metabolism of cancer cells – an approach that experts refer to as "Warburg effect reversal". Read More
Read full articleVidac Pharma – Investors applaud the latest progress
This is slowly turning into a long-term story. We have reported on Vidac Pharma plc several times in recent weeks. There has been tremendous interest in the stock recently, and even with a premium of 300% at the peak, there are now further potential buyers. Last week, the price briefly reached EUR 1.30, which seems a bit excessive in such a short time. At the peak, around 4 million shares changed hands. Since the last report on the granting of a patent for extensive protection of the mode of action of its cancer drug candidates, there have been no new insights. Presumably, expectations are high for further progress in the Israeli research program at the upcoming medical conferences in Q4, particularly regarding the drug candidates VDA-1102 and VDA-1275. Read More
Read full articleVidac Pharma: US patent makes it a takeover candidate?
Vidac Pharma's stock has been one of the positive surprises of the past few months. Driven by strong newsflow, the share price of the cancer-focused company has more than doubled since its low at the end of May at under EUR 0.18. The current consolidation at around EUR 0.30 offers an interesting entry opportunity, as analysts see the potential for a tenfold increase. The German research firm Sphene Capital recommends the Vidac share with a price target of EUR 4.90 in the base case scenario. Read More
Read full articleVidac Pharma receives broad US patent protection for novel cancer cell metabolism mechanism
Vidac Pharma (ISIN: GB00BM9XQ619), a clinical-stage biopharmaceutical company specializing in the development of a novel class of cancer treatments, has been awarded a patent by the United States Patent and Trademark Office (USPTO). This patent provides comprehensive protection for the mechanism of action underlying the Company's oncology and onco-dermatology therapeutic candidates. Read More
Read full articleVidac Pharma receives broad US patent protection for novel cancer cell metabolism mechanism
Vidac Pharma (ISIN: GB00BM9XQ619), a clinical-stage biopharmaceutical company specializing in the development of a novel class of cancer treatments, has been awarded a patent by the United States Patent and Trademark Office (USPTO). This patent provides comprehensive protection for the mechanism of action underlying the Company's oncology and onco-dermatology therapeutic candidates. Read More
Read full articleVidac Pharma in High Demand
The biopharmaceutical oncology company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker Symbol: T9G) has reported several successes this year. At the end of March 2024, the company received approval from the Japanese Patent Office for its drug candidate VDA-1275. This compound is being used in the preclinical phase against cancer cells and has already demonstrated notable success. The main molecule in VDA-1275 was able to show its effectiveness in animal trials with a variety of tumors. When VDA-1275 was used in combination with two widely-used chemotherapeutic agents, strong synergy effects were observed in lab tests on cultured human liver cells. Read More (in German)
Read full articleVidac Pharma - Small molecules against cancer
Those interested in investing in promising biotech small-caps should keep Vidac Pharma on the radar. Despite its manageable size, the Company is already in the clinical development phase. The best-known product, VDA-1275, is the focus of interest according to a specialist article, as this drug candidate for the treatment of solid tumors has achieved impressive results in preclinical studies. As a monotherapy, VDA-1275 shows significant efficacy against tumors. Even more remarkable are the synergistic effects observed when VDA-1275 is used in combination with conventional cancer therapies. Read More
Read full articleNew Financial: Multiplication and Travel Boom! Bayer, TUI, Vidac Pharma
Vidac Pharma shares have gained over 23% in the past four weeks. Driven by strong study data from the biotech company focused on fighting cancer, analysts even see the potential for multiplication. Such euphoria has been absent at Bayer for some time. However, at least there is positive momentum from the pharmaceuticals division again, which is much needed, as the Leverkusen-based company's pipeline is considered modest. In contrast, business at TUI is booming. Nevertheless, the tourism group's shares have disappointed in the current year. Will a new cruise ship take it towards EUR 10? Read More
Read full articleNew Financial: Multiplication and Travel Boom! Bayer, TUI, Vidac Pharma
Vidac Pharma shares have gained over 23% in the past four weeks. Driven by strong study data from the biotech company focused on fighting cancer, analysts even see the potential for multiplication. Such euphoria has been absent at Bayer for some time. However, at least there is positive momentum from the pharmaceuticals division again, which is much needed, as the Leverkusen-based company's pipeline is considered modest. In contrast, business at TUI is booming. Nevertheless, the tourism group's shares have disappointed in the current year. Will a new cruise ship take it towards EUR 10? Read More
Read full articleVidac Pharma - Technical report causes a stir
Vidac Pharma, a listed company in the clinical development phase, offers an exciting and promising prospect. Vidac Pharma's latest product, VDA-1275, is at the center of interest following a technical report. This innovative drug candidate for the treatment of solid tumors has achieved impressive results in preclinical studies. As a monotherapy, VDA-1275 shows significant anti-tumor efficacy. Even more remarkable are the synergistic effects observed when VDA-1275 is used in combination with conventional cancer therapies. Another positive aspect is the ability of VDA-1275 to trigger an immune response - a promising indication of its potential in cancer treatment. Read More
Read full articleVidac Pharma - Tremendous potential
The new technology being developed by Vidac Pharma, a company founded in 2012 and led by Prof. Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is groundbreaking. Vidac Pharma is researching drugs designed to help cancer patients by reversing the abnormal metabolism of cancer cells , thereby stopping the proliferation of these cells. Read More
Read full articleVidac Pharma - New results demonstrate strength
Among the biotech small-cap stocks, Vidac Pharma has recently made headlines. The British-Israeli company has recently published promising results of its studies with the promising compound VDA-1275 in several mouse and human cellular organoid models of solid tumours in a scientific article. The paper has been submitted for independent peer review. The associated study demonstrates that VDA-1275 exhibited statistically significant efficacy as a monotherapy and synergistic effects in combination with two standard cancer therapies and also elicited an immunological response. Read More
Read full articleVidac Pharma - The 1,662 percent opportunity!
A mega rally could start here, at least according to analysts who analyzed the recently published results of tests with next-generation drug candidates in human and murine tumour models. According to the analysis, Sphene Capital sees a price target of no less than EUR 4.90 for Vidac Pharma, representing a potential upside of 1,662% from the current price level of EUR 0.278. Read More
Read full articleVIDAC PHARMA, BIONTECH, GSK: PIONEERS IN MEDICAL PROGRESS - WHO WILL WIN THE RACE?
With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time, a patent dispute is raging between Moderna and BioNTech, which could significantly impact the future of mRNA technology. This makes the strategic partnership between GSK and CureVac all the more important. The British company GSK is paying billions of euros for rights to COVID-19 and flu vaccines, which CureVac is to develop. During the pandemic, CureVac was noted more for its shortcomings in vaccine development. Will they achieve a breakthrough now? Read More
Read full articleVIDAC PHARMA, BIONTECH, GSK: PIONEERS IN MEDICAL PROGRESS - WHO WILL WIN THE RACE?
With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time, a patent dispute is raging between Moderna and BioNTech, which could significantly impact the future of mRNA technology. This makes the strategic partnership between GSK and CureVac all the more important. The British company GSK is paying billions of euros for rights to COVID-19 and flu vaccines, which CureVac is to develop. During the pandemic, CureVac was noted more for its shortcomings in vaccine development. Will they achieve a breakthrough now? Read More
Read full articleVIDAC PHARMA - PATENT APPLICATION AND NEW COVERAGE
We have reported several times on Vidac Pharma plc in recent weeks. The interest in the share is enormous for a penny stock, with over 200,000 shares changing hands at times. The Company has just announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application to protect a group of molecules. These molecules can trigger an immune response in various cancers by detaching the enzyme hexokinase-2 (HK2) from the mitochondrial VDAC pores. The molecules are the key compounds in Vidac's two drug candidates, VDA-1102 and VDA-1275. For more detailed information, please visit news.financial.
Read full articleEVOTEC, VIDAC PHARMA, BAYER - BIOTECH AND PHARMA: OPPORTUNITIES FOR INVESTORS
The biopharmaceutical company Vidac Pharma, which specializes in developing innovative cancer treatments, has recently achieved a significant milestone. On June 3, the Company was awarded a key patent for its group of molecules by the US Patent and Trademark Office. These molecules can release the enzyme hexokinase-2 (HK2) from the mitochondrial VDAC pores, which triggers an immune response in various types of cancer. This advance strengthens Vidac Pharma's position in the market and demonstrates the potential of its therapies to revolutionize cancer treatment. For more detailed information, please visit news.financial.
Read full articleEVOTEC, VIDAC PHARMA, BAYER - BIOTECH AND PHARMA: OPPORTUNITIES FOR INVESTORS
The biopharmaceutical company Vidac Pharma, which specializes in developing innovative cancer treatments, has recently achieved a significant milestone. On June 3, the Company was awarded a key patent for its group of molecules by the US Patent and Trademark Office. These molecules can release the enzyme hexokinase-2 (HK2) from the mitochondrial VDAC pores, which triggers an immune response in various types of cancer. This advance strengthens Vidac Pharma's position in the market and demonstrates the potential of its therapies to revolutionize cancer treatment. For more detailed information, please visit news.financial.
Read full articleVidac Pharma on FinanzNachrichten
FinanzNachrichten provides financial news and updates specifically related to Vidac Pharma Holdings PLC. It covers the company's stock performance, recent financial news, market analysis, and any significant corporate announcements. The page serves as a resource for investors and analysts looking to stay informed about Vidac Pharma's financial status and business developments. For more detailed information, you can visit the FinanzNachrichten webpage.
Read full articleVIDAC PHARMA: WHEN WILL THE TURNAROUND COME?
Vidac Pharma has not yet broken out of its sideways movement, but this is likely only a matter of time. The London-based biotech company is making good progress in cancer research and has been traded as a takeover candidate, especially since Genmab's billion-dollar acquisition of ProfoundBio. Vidac Pharma's innovative approach has the potential to revolutionize cancer treatment. The Company is researching ways to halt the proliferation of cancer cells by reversing their abnormal metabolism. Read More
Read full articleBIOTECH AND PHARMA STOCKS FINALLY FOLLOW SUIT! NOVO NORDISK, BAYER, BIONTECH, VIDAC PHARMA AND EVOTEC ON THE BUY LIST
There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did not persist in 2024. Tough refinancing conditions have been holding the market back, according to the German website. But if an interest rate cut materializes over the summer, the outlook would look a lot brighter, according to commentator André Will-Laudien, who added Vidac Pharma to his “Buy” list, together with a selected few other stocks that would profit from an upturn. Read the Article
Read full articleBIOTECH AND PHARMA STOCKS FINALLY FOLLOW SUIT! NOVO NORDISK, BAYER, BIONTECH, VIDAC PHARMA AND EVOTEC ON THE BUY LIST
There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did not persist in 2024. Tough refinancing conditions have been holding the market back, according to the German website. But if an interest rate cut materializes over the summer, the outlook would look a lot brighter, according to commentator André Will-Laudien, who added Vidac Pharma to his “Buy” list, together with a selected few other stocks that would profit from an upturn. Read the Article
Read full articleEVOTEC, VIDAC PHARMA, BIONTECH - THE BILLION-DOLLAR RACE FOR CANCER THERAPY
Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress are driving revenues in the pharmaceutical industry. This not only underlines the enormous financial value of oncology as an investment area but also promises ground-breaking improvements in patient care. We look at three companies that could benefit from this. Read More
Read full articleEVOTEC, VIDAC PHARMA, BIONTECH - THE BILLION-DOLLAR RACE FOR CANCER THERAPY
Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress are driving revenues in the pharmaceutical industry. This not only underlines the enormous financial value of oncology as an investment area but also promises ground-breaking improvements in patient care. We look at three companies that could benefit from this. Read More
Read full articleVIDAC PHARMA - GOOD PROGRESS IN THE FIGHT AGAINST CANCER
UK and Israel-based Vidac Pharma plc (STU: T9G, WKN: A3DTUQ, ISIN: GB00BM9XQ619) is another clinical-stage biopharmaceutical company developing first-in-class oncology and oncodermatology therapies. Its breakthrough new technology, which corrects a common feature of all cancer cells, holds the promise of a fundamentally new way of treating cancer and is becoming a routine part of oncology combination therapies. Founded in 2012, the company is led by CEO Prof. Max Herzberg, one of the founding fathers of the Israeli biotech industry. Vidac Pharma develops drugs with the aim of reversing the abnormal metabolism of cancer cells and thus stopping the proliferation of cancer cells. With a strong IP portfolio, Vidac's main asset is in clinical trials for two indications, while a powerful new drug candidate with a potential broad application in solid tumors is entering preclinical testing. Vidac's lead product VDA-1102, currently in clinical development as an ointment for patients with actinic keratosis, addresses an early form of skin cancer and is being tested in a separate study for a cutaneous T-cell lymphoma (CTCL) indication. A second molecule VDA-1275, which could be used for a broad spectrum of solid tumors, has already proven to be a powerful candidate against cancer cells in ongoing preclinical studies. At the end of March 2024, Vidac received approval for VDA-1275 from the Japanese Patent Office. While the active ingredient has already been shown to be effective in a large number of tumors in animal experiments, it also demonstrates strong synergistic effects in combination with two widely used chemotherapeutic agents on human liver cells grown in the laboratory. As early as February 2024, Vidac Pharma was able to statistically significantly extend survival time in a colorectal cancer model in mice compared to the chemotherapeutic Opdivo (nivolumab) from Bristol-Myers Squibb. In a model of human liver cancer cells, the use of VDA-1275 in the laboratory reduced the administration of the cell growth inhibitors sorafenib and cisplatin and still reduced IC50 cancer cell viability by 50 % and 95 % respectively. Clinical trials are now being sought to validate the outstanding results. Vidac Pharma has been listed on the Hamburg and Stuttgart stock exchanges since mid-2023 and is very actively traded on some days. A company valuation carried out in 2023 put the enterprise value at a good EUR 80 million or EUR 1.15 per share. Due to the progress made in research, the value should quickly come to the attention of Big Pharma. A market capitalization of just under EUR 11 million in no way reflects the investments that have already been made in the company historically. A strong increase in the current year should therefore come as no surprise!
VIDAC PHARMA WITH APPROVAL NOTICE
The biopharmaceutical company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker symbol: T9G), which is based in Israel and the UK, received notification of approval for its drug candidate VDA-1275 from the Japanese Patent Office at the end of March 2024. This has already shown several promising effects in the preclinical phase and has been used against cancer cells. The new molecule used in VDA-1275 has shown direct efficacy in a large number of tumors in animal experiments. Strong synergy effects were also demonstrated when the active ingredient was combined with two widely used chemotherapeutic agents on human liver cells grown in the laboratory. As early as February 2024, Vidac Pharma was able to statistically significantly extend survival time in a colorectal cancer model in mice compared to the chemotherapeutic Opdivo (nivolumab) from Bristol-Myers Squibb (WKN: 850501 | ISIN: US1101221083 | ticker symbol: BRM). In a model of human liver cancer cells, the use of VDA-1275 in the laboratory reduced the administration of the cell growth inhibitors sorafenib and cisplatin while still reducing IC50 cancer cell viability by 50% and 95%, respectively. After evaluating these findings with other experts, clinical tests will have to follow, as the initial results look promising.
ATTENTION: BIOTECH TAKEOVERS, AFTER MORPHOSYS, NOW BAYER, VIDAC PHARMA, BIONTECH AND PFIZER ARE ON THE RADAR
Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl. Read More
Read full articleATTENTION: BIOTECH TAKEOVERS, AFTER MORPHOSYS, NOW BAYER, VIDAC PHARMA, BIONTECH AND PFIZER ARE ON THE RADAR
Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl. Read More
Read full article